Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma

Open access
Deng, Wei-Wei, Mao, Liang, Yu, Guang-Tao, Bu, Lin-Lin, Ma, Si-Rui, Liu, Bing, Gutkind, J. Silvio, Kulkarni, Ashok B., Zhang, Wen-Feng, Sun, Zhi-Jun·2016·OncoImmunology

Abstract

Immunotherapy with immune checkpoint molecule-specific monoclonal antibody have obtained encouraging results from preclinical studies and clinical trials, which promoted us to explore whether this kind of immunotherapy could be applicable to head and neck squamous cell carcinoma (HNSCC). Lymphocyte activation gene-3 (LAG-3) is an immune checkpoint control protein that negatively regulates T cells and immune response. Here, using the human tissue samples, we report these findings that LAG-3 is overexpressed on tumor-infiltrating lymphocytes (TILs; p < 0.001) and its overexpression correlates with the high pathological grades, lager tumor size and positive lymph node status in human primary HNSCC. Survival analysis identifies LAG-3 as a prognostic factor independent of tumor size and pathological grades for primary HNSCC patients with negative lymph node status (p = 0.014). Study in immunocompetent genetically defined HNSCC mouse model reports that LAG-3 is upregulated on CD4+ T cells, CD8+ T cells and CD4+Foxp3+ regulatory T cells (Tregs). In vivo study, administration of LAG-3-specific antibody retards tumor growth in a way associated with enhanced systemic antitumor response by potentiating the antitumor response of CD8+ T cells and decreasing the population of immunosuppressive cells. Taken together, our results offer a preclinical proof supporting the immunomodulatory effects of LAG-3 and suggest a potential therapeutic target of immunotherapy for HNSCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2016.1239005

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 172

Metadata

Authors
Deng, W.-W., Mao, L., Yu, G.-T., Bu, L.-L., Ma, S.-R., Liu, B., Gutkind, J. S., Kulkarni, A. B., Zhang, W.-F., & Sun, Z.-J.
Venue
OncoImmunology
Published
2016-10-07
Volume
5
Issue
11
Pages
e1239005
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2527850257
Cited by
172
References
5
FWCI
4.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. https://app.cochat.ai/papers/10.1080/2162402x.2016.1239005
The paper
Deng, W.-W., Mao, L., Yu, G.-T., Bu, L.-L., Ma, S.-R., Liu, B., Gutkind, J. S., Kulkarni, A. B., Zhang, W.-F., & Sun, Z.-J. (2016). LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. OncoImmunology. https://doi.org/10.1080/2162402x.2016.1239005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.